Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor. The aim of the study io evaluate the utility of Ezetimibe in combination with pegylated interferon in patients with chronic HDV infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Pegylated interferon alfa
Ezetimibe
Change in HDV RNA quantitative measurements of >2 logs from baseline
Time frame: 24 weeks of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.